Abstract
Lung cancer is the leading cause of cancer-related deaths in the United States due, in large part, to the lack of early detection methods. Lung cancer arises from a complex series of genetic and epigenetic changes leading to uncontrolled cell growth and metastasis. Unlike genetic changes, epigenetic changes, such as DNA methylation and histone acetylation, are reversible with currently available pharmaceuticals and are early events in lung tumorigenesis detectable by non-invasive methods. In order to better understand how epigenetic changes contribute to lung cancer, and to identify new disease biomarkers, we combined pharmacologic inhibition of DNA methylation and histone deacetylation in non-small cell lung cancer (NSCLC) cell lines, with genome-wide expression profiling. Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally downregulated in NSCLC cell lines and tumors. Interestingly, four other genes, cylindromatosis, CD9, activating transcription factor 3 and oxytocin receptor, were dominantly regulated by histone deacetylation and were also frequently downregulated in lung tumors. The majority of these genes also suppressed NSCLC growth in culture when ectopically expressed. This study therefore reveals new putative NSCLC growth regulatory genes and epigenetic disease biomarkers that may enhance early detection strategies and serve as therapeutic targets.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abrahamson M, Alvarez-Fernandez M, Nathanson C-M . (2003). Cystatins. Biochem Soc Symp 70: 179–199.
Ai L, Kim W-J, Kim T-Y, Fields CR, Massoll NA, Robertson KD et al. (2006). Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res 66: 7899–7909.
Belinsky SA . (2004). Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 1–11.
Belinsky SA, Klinge DM, Stidley CA, Issa J-P, Herman JG, March TH et al. (2003). Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 63: 7089–7093.
Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E et al. (1998). Aberrant methylation of 16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891–11896.
Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R et al. (2000). Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 25: 160–165.
Bird A . (2002). DNA methylation patterns and epigenetic memory. Genes Dev 16: 6–21.
Bottone FGJ, Martinez JM, Collins JB, Afshari CA, Eling TE . (2003). Gene modulation by the cyclooxygenase inhibitor, suldinac sulfide, in human colorectal carcinoma cells. J Biol Chem 278: 25790–25801.
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB . (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103–107.
Cassoni P, Sapino A, Marrocco T, Chin B, Bussolati G . (2004). Oxytocin and oxytocin receptors in cancer cells and proliferation. J Neuroendocrinol 16: 362–364.
Chen H, Pan Y-X, Dudenhausen EE, Kilberg MS . (2004). Amino acid deprivation induces the transcription rate of the human asparagine synthetase gene through a timed program of expression and promoter binding of nutrient-responsive basic region/leucine zipper transcription factors as well as localized histone acetylation. J Biol Chem 279: 50829–50839.
Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R . (1998). DNA hypomethylation leads to elevated mutation rates. Nature 395: 89–93.
Clyde-Smith J, Silins G, Gartside M, Grimmond S, Etheridge M, Apolloni A et al. (2000). Characterization of RasGRP2, a plasma membrane-targeted, dual specificity Ras/Rap exchange factor. J Biol Chem 275: 32260–32267.
Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S et al. (2003). Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299: 1753–1755.
Digel W, Lubbert M . (2005). DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit Rev Oncol Hematol 55: 1–11.
Dutta R, Sens DA, Somji S, Sens MA, Garrett SH . (2002). Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells. Prostate 52: 89–97.
Eickoff B, Ruller S, Laue T, Kohler G, Stahl C, Schlaak M et al. (2000). Trichostatin A modulates expression of p21waf1/cip1, Bcl-XL, ID1, ID2, ID3, CRAB2, GATA-1, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells. Biol Chem 381: 107–112.
Espada J, Ballestar E, Fraga MF, Villar-Garea A, Juarranz A, Stocker JC et al. (2004). Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern. J Biol Chem 279: 37175–37184.
Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG . (1999). Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum from non-small cell lung cancer patients. Cancer Res 59: 67–70.
Evans HK, Wylie AA, Murphy SK, Jirtle RL . (2001). The neuronatin gene resides in a micro-imprinted domain on human chromosome 20q11.2. Genomics 77: 99–104.
Feinberg AP, Tycko B . (2004). The history of cancer epigenetics. Nat Rev Cancer 4: 1–11.
Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A et al. (2005). Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65: 1141–1145.
Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al. (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391–400.
Frommer M, Mc Donald LE, Millar DS, Collis CM, Watt F, Grigg GW et al. (1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89: 1827–1831.
Garber ME, Troyanskaya OG, Schuens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M et al. (2001). Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98: 13784–13789.
Gius D, Cui H, Bradbury CM, Cook J, Smart DK, Zhao S et al. (2004). Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6: 361–371.
Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U . (1999). ATF3 and stress response. Gene Exp 7: 321–335.
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . (1996). Methylation-specific PCR: A novel assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821–9826.
Higashiyama M, Taki T, Ieki Y, Adachi M, Huang CL, Koh T et al. (1995). Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 55: 6040–6044.
Jenuwein T, Allis CD . (2001). Translating the histone code. Science 293: 1074–1080.
Jones PA, Baylin SB . (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415–428.
Karpf AR, Peterson PW, Rawlins JT, Dalley BK, Yang Q, Albertsen H et al. (1999). Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci USA 96: 14007–14012.
Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F . (2003). Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291–7300.
Kim T-Y, Zhong S, Fields CR, Kim JH, Robertson KD . (2006). Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 66: 7490–7501.
Kuerbitz S, Pahys J, Wilson A, Compitello N, Gray TA . (2002). Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia. Carcinogenesis 23: 559–564.
Maecker HT, Todd SC, Levy S . (1997). The tetraspanin superfamily: molecular interactions. FASEB J 11: 428–442.
Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar AF . (2004). Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 100: 1472–1477.
Mazieres J, He B, Xu Z, Lee AY, Mikami I, Reguart N et al. (2004). Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64: 4717–4720.
Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG . (1999). In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 96: 12754–12759.
Pequeux C, Breton C, Hagelstein M-T, Geenen V, Legros J-J . (2005). Oxytocin receptor pattern of expression in primary lung cancer and in normal lung. Lung Cancer 50: 177–188.
Ramaswamy S, Ross KN, Lander ES, Golub TR . (2003). A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49–54.
Rhee I, Bachman KE, Park BH, Jair K-W, Yen R-WC, Schuebel KE et al. (2002). DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416: 552–556.
Robertson KD . (2002). DNA methylation and chromatin – unraveling the tangled web. Oncogene 21: 5361–5379.
Sato N, Maehara N, Su SG, Goggins M . (2003). Effects of 5-aza-2′-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 95: 327–330.
Schrump DS, Nguyen DM . (2005). Targeting the epigenome for the treatment and prevention of lung cancer. Semin Oncol 32: 488–502.
Somech R, Izraeli S, Simon AJ . (2004). Histone deacetylase inhibitors – a new tool to treat cancer. Cancer Treat Rev 30: 461–472.
Suh YH, Kim WH, Moon C, Hong YH, Eun S-Y, Lim JH et al. (2005). Ectopic expression of neuronatin potentiates adipogenesis through enhanced phosphorylation of cAMP-response element-binding protein in 3T3-L1 cells. Biochem Biophys Res Commun 337: 481–489.
Topaloglu O, Hoque MO, Tokumaru Y, Lee J, Rativitski E, Sidransky D et al. (2004). Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 10: 2284–2288.
Trompouki E, Hatzivassillou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G . (2003). CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Science 424: 793–796.
Wang L, Baiocchi RA, Pal S, Mosialos G, Caligiuri M, Sif S . (2005). The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol 25: 7953–7965.
Yan C, Lu D, Hai T, Boyd DD . (2005). Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. EMBO J 24: 2425–2435.
Acknowledgements
This work was supported by NIH Grants K22CA084535 and R01CA114229 (KDR). We thank Bert Vogelstein and Lei Xiao for providing cell lines, Mick Popp and Li Liu for assistance with the microarray analysis, Martha Campbell-Thompson for providing tumor samples and Michael Kilberg for critical reading of the paper. We also thank Xose Bustelo, George Mosialos and Hansoo Lee for providing plasmids.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Zhong, S., Fields, C., Su, N. et al. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26, 2621–2634 (2007). https://doi.org/10.1038/sj.onc.1210041
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210041
Keywords
This article is cited by
-
Competitive ubiquitination activates the tumor suppressor p53
Cell Death & Differentiation (2020)
-
Loss of CYLD accelerates melanoma development and progression in the Tg(Grm1) melanoma mouse model
Oncogenesis (2019)
-
Targeting deubiquitinase USP28 for cancer therapy
Cell Death & Disease (2018)
-
Atf3 deficiency promotes genome instability and spontaneous tumorigenesis in mice
Oncogene (2018)
-
Dishevelled proteins and CYLD reciprocally regulate each other in CML cell lines
Molecular Biology Reports (2017)